Get the Stockscreener App
109.51
5.48%
-6.35
Veradermics Inc stock is traded at $109.51, with a volume of 532.97K.
It is down -5.48% in the last 24 hours and down -6.63% over the past month.
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
See More
Previous Close:
$115.86
Open:
$115.4
24h Volume:
532.97K
Relative Volume:
0.78
Market Cap:
$4.58B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-116.50
EPS:
-0.94
Net Cash Flow:
-
1W Performance:
-1.63%
1M Performance:
-6.63%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$109.27
$117.93
1-Week Range:
$104.45
$117.93
52-Week Range:
$32.00
$131.24
Veradermics Inc Stock (MANE) Company Profile
Name
Veradermics Inc
Sector
Industry
Phone
228.372.3376
Address
470 JAMES STREET, NEW HAVEN
Compare MANE vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MANE
Veradermics Inc
|
109.51 | 4.58B | 0 | 0 | 0 | -0.94 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Veradermics Inc Stock (MANE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-02-26 | Initiated | Citigroup | Buy |
| Mar-02-26 | Initiated | Jefferies | Buy |
| Mar-02-26 | Initiated | Leerink Partners | Outperform |
Veradermics Inc Stock (MANE) Latest News
Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Veradermics shares climb 9% after encouraging female hair loss trial results (MANE) - MSN
Veradermics presents subgroup analysis of hair loss drug trial By Investing.com - Investing.com Canada
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy - Yahoo Finance
Veradermics Is Maintained at Buy by Citigroup - Moomoo
MANE Maintained by Citigroup -- Price Target Raised to $160 - GuruFocus
Why Veradermics Stock Fell Today - Quiver Quantitative
Veradermics keeps ‘momentum going’ as baldness drug helps women with hair loss - BioPharma Dive
Veradermics stock jumps again on female hair loss drug win - Clinical Trials Arena
Veradermics jumps after mid-stage trial data for lead drug in female pattern hair loss - MSN
MANE Stock Draws Traders As Volatility And Cash Pile Stand Out - StocksToTrade
Why is MANE stock rising today? - MSN
LifeSci Capital Maintains Veradermics(MANE.US) With Buy Rating, Raises Target Price to $170 - Moomoo
Why Is MANE Stock Rising Today? - TradingView
Buzzy Veradermics shows its oral minoxidil can tackle female pattern hair loss, too - Fierce Pharma
Veradermics (MANE) Sees 13.9% Increase in Stock Price - GuruFocus
Veradermics Hair Loss Pill Shows Strong Phase II Signal in Women - Yahoo Finance
PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On Wednesday - Benzinga
Veradermics stock rises 9% on positive hair loss trial data By Investing.com - Investing.com Canada
Veradermics (NYSE: MANE) posts strong VDPHL01 Phase 2 female data - Stock Titan
Veradermics stock rises 9% on positive hair loss trial data - Investing.com
MANE Initiates Coverage by B. Riley Securities -- Price Target S - GuruFocus
Veradermics reports phase 2 hair loss trial results By Investing.com - Investing.com Canada
Up to 90% of women reported better hair coverage by Month 6 - Stock Titan
Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout - Yahoo Finance
B.Riley initiates Veradermics stock coverage with Buy on hair loss drug - Investing.com Nigeria
B.Riley initiates Veradermics stock coverage with Buy on hair loss drug By Investing.com - Investing.com India
Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss - BioSpace
Veradermics Announces Encouraging Phase 2 Results for VDPHL01 in Female Pattern Hair Loss with Over 22 Hairs/cm² Average Growth - Kalkine Media
Veradermics to present phase 2 hair loss study results Wednesday - Investing.com
Veradermics to Share Hair Loss Drug Study Results in Wednesday Call - Moomoo
Veradermics to present phase 2 hair loss study results Wednesday By Investing.com - Investing.com Canada
MSN Money - MSN
Veradermics (MANE) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Jefferies Maintains Veradermics(MANE.US) With Buy Rating, Raises Target Price to $182 - Moomoo
Veradermics (MANE) Stock Forecast & Analyst Ratings - Moomoo
Hair loss biotech Veradermics, up 656% since its IPO, credits the obesity boom - BioSpace
MANE Should I Buy - Intellectia AI
Veradermics, Incorporated(NYSE: MANE) added to Russell 2000 Index - marketscreener.com
Veradermics, Incorporated(NYSE: MANE) added to Russell 2000 Value Benchmark - marketscreener.com
Veradermics, Incorporated(NYSE: MANE) added to Russell 2000 Growth Benchmark - marketscreener.com
Veradermics, Incorporated(NYSE: MANE) added to Russell 3000E Growth Benchmark - marketscreener.com
2026 Power 25 Healthcare: Dr. Reid Waldman - Hartford Business Journal
Veradermics, Incorporated(NYSE: MANE) added to Russell 3000 Growth Benchmark - marketscreener.com
Veradermics, Incorporated(NYSE: MANE) added to Russell Small Cap Completeness Index - marketscreener.com
Veradermics, Incorporated Actuals & Estimates (NYSE:MANE) - TradingView
Cantor Fitzgerald reiterates Veradermics stock rating after CEO dinner By Investing.com - Investing.com Australia
MANE Forecast — Price Target — Prediction for 2027 - TradingView
Biotech ETF Index Surges 10% After Rebalance - ETF Database
MANE Stock Pops As Traders Hunt Biotech Momentum - StocksToTrade
Veradermics Inc Stock (MANE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):